»Glycotest™ Intellectual Property Portfolio Expanded by United Sates, European and Australian Patents
07 Jul, 2017

New York, NY—July 07, 2017—Glycotest, Inc. announced today that a European patent has been granted and additional United States and Australian patents have been allowed. Together these patents will extend protection of the Company’s core technology for early detection of life threatening liver disease.

Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and increase survival for the growing population at risk from serious liver diseases. Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry.

The granted European and allowed United States and Australian patents announced today join six other patents previously granted in the United States, Japan and Australia which have been licensed exclusively and on a worldwide basis to Glycotest by Drexel University College of Medicine and the Blumberg Institute of the Hepatitis B Foundation, both in the Philadelphia area. These patents cover the use of over 50 unique glycoprotein biomarkers as well as related assay technology for the diagnosis of liver cancers and other liver diseases. Together the granted patents and the additional pending applications protect Glycotest’s proprietary liver disease diagnostic platform.

Commenting on these developments, Glycotest’s Chief Executive Officer Lawrence Cohen said, “The Glycotest patent portfolio is expanding in both the breadth of our technology protection and the jurisdictions in which we have granted patents. We anticipate continued good news regarding our intellectual property portfolio which we expect to form the basis of a strong position in the liver disease diagnostics space.



About Glycotest, Inc.

Glycotest is a private liver disease diagnostics company commercializing novel clinical laboratory testing services for patients at risk for liver cancers and fibrosis-cirrhosis. The Company was founded in 2012 on proprietary technology that originated at the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine. Learn more at